Edition:
India

Capricor Therapeutics Inc (CAPR.OQ)

CAPR.OQ on NASDAQ Stock Exchange Capital Market

1.65USD
15 Dec 2017
Change (% chg)

$0.06 (+3.77%)
Prev Close
$1.59
Open
$1.60
Day's High
$1.69
Day's Low
$1.60
Volume
29,566
Avg. Vol
279,064
52-wk High
$4.25
52-wk Low
$0.63

Select another date:

Wed, Nov 29 2017

BRIEF-Capricor Therapeutics Says FDA Cleared IND Application For CAP-1002

* CAPRICOR THERAPEUTICS ANNOUNCES FDA CLEARANCE OF INVESTIGATIONAL NEW DRUG (IND) APPLICATION FOR CAP-1002

BRIEF-Capricor Therapeutics reports Q3 loss per share $0.12

* Capricor Therapeutics reports third quarter 2017 financial results and provides update on duchenne muscular dystrophy development program

BRIEF-Capricor says results from Duchenne muscular dystrophy trial to be presented at AHA late-breaking session

* Capricor announces 12-month results from HOPE-1 trial in Duchenne muscular dystrophy to be presented at AHA late-breaking session Source text for Eikon: Further company coverage:

BRIEF-Capricor Therapeutics ‍enters into common stock sales agreement

* Capricor Therapeutics - ‍entered into common stock sales agreement - sec filing

BRIEF-Capricor Therapeutics advances clinical development program in Duchenne muscular dystrophy

* Capricor Therapeutics advances clinical development program in Duchenne muscular dystrophy with naming of principal investigator

BRIEF-Capricor to present 6-month results from the randomized hope trial of CAP-1002

* Capricor Therapeutics to present six-month results from the randomized hope trial of CAP-1002 in duchenne muscular dystrophy in a late breaking session of the world muscle society Source text for Eikon: Further company coverage:

BRIEF-Capricor Therapeutics Q2 loss per share $0.16

* Capricor Therapeutics reports second quarter 2017 financial results and provides corporate update

BRIEF-Capricor Therapeutics retains full rights to CAP-1002 as Janssen Biotech decides not to exercise option

* Capricor therapeutics- no payments between capricor and janssen are required to be made in relation to this decision

Select another date: